Comparison of Thrice-daily Novomix Insulin Versus Insulin Glargine Once-Daily Combined with Thrice-Daily Insulin Aspart on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

• Published in: Iranian journal of diabetes and obesity 2024-08, Vol.16 (3), p.149-153
• Main Authors: Seyyed Hossein Mirtorabi, Roghaye Razavi, Roghaye Mirjalili, Nasim Namiranian, Mozhgan Modarresi, Reyhaneh Azizi
• Format: Article
• Language: English
• Subjects: diabetes mellitus; glycemic control; insulin aspart; insulin glargine; type 2
• ISSN: 2008-6792; 2345-2250

Objective: The objective of the present analysis was to compare the effect of these two treatment regimens (Novomix insulin twice or thrice-daily versus once-daily insulin glargine plus twice or thrice-daily insulin aspart) on glycemic control in Iranian patients with T2DM. Materials and Methods: This cross-sectional study was conducted for one year on people with type 2 diabetes referred to Yazd Medical Research Center. Glycemic control (HbA1C, FBG, and 2hPP) from baseline (week 0) to 24 -48 weeks were recorded in the electronic file of patients receiving Novomix insulin twice or thrice daily. These profiles were compared to those of patients receiving once-daily insulin glargine plus twice or thrice-daily insulin aspart (according to each meal). P< 0.05 was considered as a significant level. Results: Based on the finding, both treatment groups demonstrated significant reductions in FBG, 2hPP, and HbA1c from baseline to the study endpoint (weeks 24 and 48) (P< 0.05 for all comparisons). However, the changes in HbA1c, FBG, and 2hPP levels compared to the baseline level during the study were not significant between the two groups. Conclusion: The insulin glargine regime is effective in reducing HbA1C-FBS-2HPP compared to aspart and Novomix, but no significant difference was seen between the two mentioned regimes. It is recommended to observe more effectiveness and achieve more efficient and reliable results of the studies.